Neovacs S.Aの収入
Neovacs S.Aの収入 は何ですか。
Neovacs S.A.の収入 は-5.49€です。
収入 の定義は何ですか。
普通株主に帰属する当期純利益は、純利益から優先配当金を差し引いた金額です。優先配当
Net income available to common shareholders are the profits remaining after the company pays all of its suppliers, employees, service providers, creditors, and preferred shareholders. In other words, this is revenue less all expenses and preferred dividends. The number measures common shareholders' claim on the company's cash flows.
EURONEXTのセクタHealth Careにおける収入 の企業と比べるNeovacs S.A
Neovacs S.Aは何をしますか。
Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
Neovacs S.Aと類似の収入
- Micron Waste Technologies Incの収入 は-5.52CAD$です。
- New Dimension Resourcesの収入 は-5.52CAD$です。
- Cipherlocの収入 は-5.52$です。
- Southernの収入 は-5.51$です。
- Matador Miningの収入 は-5.51AUD$です。
- Max Resourceの収入 は-5.49CAD$です。
- Neovacs S.Aの収入 は-5.49€です。
- Blue Sky Uraniumの収入 は-5.49CAD$です。
- Omai Gold Mines Corpの収入 は-5.48$です。
- Pressure Technologies plcの収入 は-5.48£です。
- Xeros Technology Plcの収入 は-5.48£です。
- Mirasol Resourcesの収入 は-5.47CAD$です。
- Modivの収入 は-5.47$です。